Elanco/ELAN

$17.08

0.23%
-
1D1W1MYTD1YMAX

About Elanco

Elanco Animal Health Incorporated is an animal health company. The Company is focused in delivering products and services to prevent and treat disease in farm animals and pets. Its portfolio serves animals across its core species consisting of dogs, cats and cattle, poultry, swine, sheep and aqua. It offers products in two primary categories: Pet Health and Farm Animal. Its Pet Health portfolio is focused on parasiticides, vaccines and therapeutics. Its Pet Health portfolio products that protect pets from fleas, ticks and internal parasites. Its Farm Animal portfolio of products is primarily focused on cattle, swine, poultry, and aquaculture. Its Pet Health products include Advantage Family, Atopica, Claro/ Neptra, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its Farm Animal products include AviPro, Baycox, Catosal, Comforta, Denagard, Experior, Hemicell, Maxiban, Monteban, Pulmotil, Rumensin, and others.

Ticker

ELAN

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

Jeffrey Simmons

Employees

9,300

Headquarters

Greenfield, United States
Website
www.elanco.com

Elanco Metrics

BasicAdvanced
$8.4B
Market cap
-
P/E ratio
-$2.64
EPS
1.44
Beta
-
Dividend rate
$8.4B
1.43712
$17.43
$7.88
4.4M
3.287
1.958
94.567
95.195
0.85%
-8.74%
-19.24%
-9.65%
1.932
1.393
30.339
-1.67%
-4,520.51%
10.53%

What the Analysts think about Elanco

Analyst Ratings

Majority rating from 15 analysts.
Buy

Price Targets

Average projection from 10 analysts.
14.34% upside
High $23.00
Low $16.00
$17.08
Current price
$19.53
Average price target

Elanco Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
2.65% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.2B
16.43%
Net income
$32M
-122.7%
Profit margin
2.65%
-119.46%

Elanco Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 28.93%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.18
$0.18
$0.08
$0.34
-
Expected
$0.05
$0.12
$0.11
$0.26
$0.24
Surprise
276.74%
51.4%
-24.53%
28.93%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Elanco stock?

Elanco (ELAN) has a market cap of $8.4B as of May 17, 2024.

What is the P/E ratio for Elanco stock?

The price to earnings (P/E) ratio for Elanco (ELAN) stock is 0 as of May 17, 2024.

Does Elanco stock pay dividends?

No, Elanco (ELAN) stock does not pay dividends to its shareholders as of May 17, 2024.

When is the next Elanco dividend payment date?

Elanco (ELAN) stock does not pay dividends to its shareholders.

What is the beta indicator for Elanco?

Elanco (ELAN) has a beta rating of 1.44. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Elanco stock price target?

The target price for Elanco (ELAN) stock is $19.53, which is 15.02% above the current price of $16.98. This is an average based on projections from 10 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Elanco stock

Buy or sell Elanco stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing